Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Łukasz Wołowiec, Joanna Osiak, Anna Wołowiec, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 323-323
Open Access | Times Cited: 18

Showing 18 citing articles:

Precision medicine for personalized cholecystitis care: integrating molecular diagnostics and biotherapeutics
Tamer A. Addissouky
Bulletin of the National Research Centre/Bulletin of the National Research Center (2024) Vol. 48, Iss. 1
Open Access | Times Cited: 4
The Plethora of RNA–Protein Interactions Model a Basis for RNA Therapies
Stephen Dansereau, Hua Cui, Ricky Dartawan, et al.
Genes (2025) Vol. 16, Iss. 1, pp. 48-48
Open Access
Familial Hypercholesterolemia: A Comprehensive Review of Advances in Treatment Strategies and the Role of Patient Beliefs
Hadi A. Bakour, Jumana Hussain Timraz, Bushra Wadi Bin Saddiq, et al.
Cureus (2025)
Open Access
MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment
Łukasz Wołowiec, Martyna Mędlewska, Joanna Osiak, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9735-9735
Open Access | Times Cited: 12
Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia
Rita Ngozi Aguchem, Innocent Uzochukwu Okagu, Ekezie Matthew Okorigwe, et al.
Life Sciences (2024) Vol. 351, pp. 122823-122823
Open Access | Times Cited: 3
Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database
Dan Zou, Qiaozhi Hu, Ying Liu, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 6, pp. 1419-1426
Closed Access | Times Cited: 3
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children
M. Doortje Reijman, D. Meeike Kusters, Albert Wiegman
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 4, pp. 243-249
Open Access | Times Cited: 2
Small interfering RNA (siRNA) as a potential gene silencing strategy for diabetes and associated complications: challenges and future perspectives
Pranali Waghode, Sheikh Shahnawaz Quadir, Deepak Choudhary, et al.
Journal of Diabetes & Metabolic Disorders (2024) Vol. 23, Iss. 1, pp. 365-383
Closed Access | Times Cited: 2
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
Rosaria Vincenza Giglio, Emir Muzurović, Angelo Maria Patti, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2023) Vol. 28
Open Access | Times Cited: 6
siRNA a promising tool for diabetes complications
Moqbel Ali Moqbel Redhwan, Hariprasad M.G, Suman Samaddar, et al.
OpenNano (2023) Vol. 13, pp. 100174-100174
Open Access | Times Cited: 5
Naringenin modulates oxidative stress and lipid metabolism: Insights from network pharmacology, mendelian randomization, and molecular docking
Jian Gao, Linjie Yuan, Huanyu Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Emerging therapies for refractory hypercholesterolemia: a narrative review
Agnieszka Pawlos, Étienne Khoury, Daniel Gaudet
Future Cardiology (2024) Vol. 20, Iss. 5-6, pp. 317-334
Closed Access
Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk
Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, et al.
Medicina (2024) Vol. 60, Iss. 7, pp. 1124-1124
Open Access
Adverse events associated with inclisiran: a real-world disproportionality analysis based on the FAERS database
Xuyang Cai, Shaopeng Peng, Shangzhen Mu, et al.
Expert Opinion on Drug Safety (2024), pp. 1-6
Closed Access
Advancements In Pharmacotherapy for Hyperlipidemia: A Comprehensive Review of Recent Drug Innovations and Clinical Outcomes
Hrithik Dey, Vatsala Agarwal, MD Naushad Ali, et al.
Journal of Drug Delivery and Therapeutics (2024) Vol. 14, Iss. 4, pp. 111-122
Open Access
Therapeutic approach in the treatment of dyslipidemia: Novelties and challenges
Katarina Lalić, N. Rajković, Ljiljana Popović, et al.
Galenika Medical Journal (2024) Vol. 3, Iss. 9, pp. 31-39
Open Access
Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: A case series
Beatrice Dal Pino, Federico Bigazzi, Francesco Sbrana
Therapeutic Apheresis and Dialysis (2023) Vol. 27, Iss. 5, pp. 978-979
Closed Access | Times Cited: 1
PCSK9 siRNA INHIBITOR INCLISIRAN AS A TREATMENT OPTION IN HYPERCHOLESTEROLEMIA: A BRIEF REVIEW
Mustafa Eray Kılıç
TURKISH MEDICAL STUDENT JOURNAL (2023) Vol. 10, Iss. 3, pp. 105-111
Open Access
Page 1

Scroll to top